



Clinical trial results:

A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with Nonalcoholic Fatty Liver (NAFL).

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-000645-12 |
| Trial protocol | NL |
| Global end of trial date | 14 July 2020 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 24 November 2021 |
| First version publication date | 24 November 2021 |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | GFT505-219-8 |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03953456 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GENFIT |
| Sponsor organisation address | Parc Eurasanté, 885, Avenue Eugène Avinée, Loos, France, 59120 |
| Public contact | clinicaltrial@genfit.com , GENFIT, +33 320164038, |
| Scientific contact | Carol Addy, MD MSc, GENFIT, +01 6179536469, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 14 July 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 14 July 2020 |
| Global end of trial reached? | Yes |
| Global end of trial date | 14 July 2020 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate the effect of a 6-week treatment with elafibranor versus placebo on hepatic lipid composition in subjects with a fatty liver.

The secondary objectives were to evaluate the between-treatment difference (elafibranor 120 mg/day vs. placebo) in hepatic glucose production (HGP) measured at the end of 6 weeks of treatment, and to compare the changes from baseline achieved after 6 weeks of treatment with elafibranor 120 mg/day versus placebo in glucose homeostasis, lipid metabolism, inflammatory markers, liver function, renal function and anthropometry.

The safety objectives were to assess the safety and tolerability profile of 6 weeks elafibranor administration orally (120 mg/day) in NAFL subjects in terms of serious adverse events (SAE), adverse events (AE), vital signs, haematological parameters, liver markers, renal biomarkers, metabolic parameters and other biochemical safety markers.

Protection of trial subjects:

This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 20 August 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | Netherlands: 17 |
| Worldwide total number of subjects | 17 |
| EEA total number of subjects | 17 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|----|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 5 |
| From 65 to 84 years | 12 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

A liver fat percentage (intrahepatic lipid [IHL]) of $\geq 5\%$ as determined with magnetic resonance spectroscopy (1H-MRS), body mass index (BMI) between 25 and 38 kg/m², and age between 40 and 75 years.

Pre-assignment

Screening details:

A total of 36 subjects were screened for the study: 19 subjects were screen failures (18 subjects did not meet the study eligibility criteria and 1 subject had low quality 1H-MRS data that made determination of liver fat composition not possible) and 17 subjects were eligible and randomised.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Blinding implementation details:

A randomisation list was generated by a random number system. Individual randomisation code referred to either of the two sequence groups: sequence Group A: placebo first followed by elafibranor 120mg, sequence Group B: elafibranor 120mg first followed by placebo. The subjects who successfully passed screening were assigned an individual randomisation code and randomly allocated to one of the two sequence groups (A or B).

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | No |
| Arm title | Elafibranor 120 mg |

Arm description:

Elafibranor 120 mg tablet qd

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Elafibranor |
| Investigational medicinal product code | GFT505 |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Elafibranor 120 mg was administered orally to study subjects once daily for 6 weeks.

| | |
|------------------|---------|
| Arm title | Placebo |
|------------------|---------|

Arm description:

Matched placebo tablet qd

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | - |
| Other name | - |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo was administered orally to study subjects once daily for 6 weeks.

| Number of subjects in period 1 | Elafibranor 120 mg | Placebo |
|--|--------------------|---------|
| Started | 13 | 13 |
| Completed | 12 | 11 |
| Not completed | 1 | 2 |
| Study interrupted due to COVID-19 pandemic | 1 | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | overall trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | overall trial | Total | |
|---|---------------|-------|--|
| Number of subjects | 17 | 17 | |
| Age categorical | | | |
| To be eligible to participate in this study, a subject had to be male or a post-menopausal female aged 40 to 75 years, inclusive, at the first Screening Visit. Post-menopausal was defined as surgically sterilised at least 6 months previously or having had no spontaneous menses for at least 1 year prior to screening. | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 5 | 5 | |
| From 65-84 years | 12 | 12 | |
| 85 years and over | 0 | 0 | |
| Adults until 64 years | 0 | 0 | |
| Adults up to 64 years inclusive | 0 | 0 | |
| Adults aged 65 to 74 years inclusive | 0 | 0 | |
| 51 to 64 years inclusive | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 65.6 | | |
| standard deviation | ± 8.2 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 3 | 3 | |
| Male | 14 | 14 | |
| Alcohol consumption | | | |
| Subjects were excluded from the study if they presented a current or recent history (<5 years) of significant alcohol consumption. For men, significant consumption was typically defined as more than 30 g pure alcohol per day; for women, it was typically defined as more than 20 g pure alcohol per day. | | | |
| Units: Subjects | | | |
| No alcohol consumption | 3 | 3 | |
| Current alcohol consumption | 14 | 14 | |
| Smoking status | | | |
| Smoking was an exclusion criterion. | | | |
| Units: Subjects | | | |
| Current smoker | 0 | 0 | |
| Not a current smoker | 17 | 17 | |
| Dietary habits and lifestyle | | | |
| Is the patient currently following a diet or strenuous physical activity to lose weight | | | |

| | | | |
|---|------------|----|--|
| Units: Subjects | | | |
| Current practice to lose weight | 0 | 0 | |
| No attempted practice to lose weight | 17 | 17 | |
| Race | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | |
| Native Hawaiian or other Pacific Islander | 0 | 0 | |
| Asian | 0 | 0 | |
| White | 17 | 17 | |
| Black or African American | 0 | 0 | |
| Other | 0 | 0 | |
| BMI categorical | | | |
| Units: Subjects | | | |
| <18.5 kg/m2 | 0 | 0 | |
| [18.5 - 25 [kg/m2 | 0 | 0 | |
| [25 - 30 [kg/m2 | 9 | 9 | |
| 30 =< | 8 | 8 | |
| BMI | | | |
| Subjects had to present a BMI of ≥ 25.0 kg/m2 but ≤ 38.0 kg/m2 to be included in the study | | | |
| Units: kg/m2 | | | |
| arithmetic mean | 30.5 | | |
| standard deviation | ± 2.3 | - | |
| Waist circumference | | | |
| Waist circumference was measured at the midpoint between the lateral iliac crest and lowest rib, during expiration. The measuring tape was to be snug but not compressing the skin and held parallel to the floor. The measurement was to be made during normal respiration. | | | |
| Units: cm | | | |
| arithmetic mean | 110.2 | | |
| standard deviation | ± 7.3 | - | |
| Fat mass (absolute) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 35.51 | | |
| standard deviation | ± 8.58 | - | |
| Fat mass (relative) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: percentage | | | |
| arithmetic mean | 38.35 | | |
| standard deviation | ± 7.57 | - | |
| Fat free mass (absolute) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 56.70 | | |
| standard deviation | ± 7.79 | - | |

| | | | |
|---|--------|---|--|
| Fat free mass (relative) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: percentage | | | |
| arithmetic mean | 61.65 | | |
| standard deviation | ± 7.57 | - | |
| Body mass | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 92.20 | | |
| standard deviation | ± 9.30 | - | |

Subject analysis sets

| | |
|--|--------------------|
| Subject analysis set title | ITT set |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: All the subjects that were randomized. | |
| Subject analysis set title | PP set |
| Subject analysis set type | Per protocol |
| Subject analysis set description: All randomized subjects who completed the study without any major protocol deviation affecting the primary efficacy endpoint. | |
| Subject analysis set title | Safety set |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: All subjects who received at least one dose of study treatment. | |

| Reporting group values | ITT set | PP set | Safety set |
|---|---------|--------|------------|
| Number of subjects | 17 | 6 | 17 |
| Age categorical | | | |
| To be eligible to participate in this study, a subject had to be male or a post-menopausal female aged 40 to 75 years, inclusive, at the first Screening Visit. Post-menopausal was defined as surgically sterilised at least 6 months previously or having had no spontaneous menses for at least 1 year prior to screening. | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 5 | 3 | 5 |
| From 65-84 years | 12 | 3 | 12 |
| 85 years and over | 0 | 0 | 0 |
| Adults until 64 years | 0 | 0 | 0 |
| Adults up to 64 years inclusive | 0 | 0 | 0 |
| Adults aged 65 to 74 years inclusive | 0 | 0 | 0 |

| | | | |
|--------------------------|---|---|---|
| 51 to 64 years inclusive | 0 | 0 | 0 |
|--------------------------|---|---|---|

| | | | |
|---|-------|---|-------|
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 65.6 | - | 65.6 |
| standard deviation | ± 8.2 | ± | ± 8.2 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 3 | | 3 |
| Male | 14 | | 14 |
| Alcohol consumption | | | |
| Subjects were excluded from the study if they presented a current or recent history (<5 years) of significant alcohol consumption. For men, significant consumption was typically defined as more than 30 g pure alcohol per day; for women, it was typically defined as more than 20 g pure alcohol per day. | | | |
| Units: Subjects | | | |
| No alcohol consumption | 3 | | 3 |
| Current alcohol consumption | 14 | | 14 |
| Smoking status | | | |
| Smoking was an exclusion criterion. | | | |
| Units: Subjects | | | |
| Current smoker | 0 | | 0 |
| Not a current smoker | 17 | | 17 |
| Dietary habits and lifestyle | | | |
| Is the patient currently following a diet or strenuous physical activity to lose weight | | | |
| Units: Subjects | | | |
| Current practice to lose weight | 0 | | 0 |
| No attempted practice to lose weight | 17 | | 17 |
| Race | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | 0 |
| Native Hawaiian or other Pacific Islander | 0 | | 0 |
| Asian | 0 | | 0 |
| White | 17 | | 17 |
| Black or African American | 0 | | 0 |
| Other | 0 | | 0 |
| BMI categorical | | | |
| Units: Subjects | | | |
| <18.5 kg/m2 | 0 | | 0 |
| [18.5 - 25 [kg/m2 | 0 | | 0 |
| [25 - 30 [kg/m2 | 9 | | 9 |
| 30 =< | 8 | | 8 |
| BMI | | | |
| Subjects had to present a BMI of ≥25.0 kg/m2 but ≤38.0 kg/m2 to be included in the study | | | |
| Units: kg/m2 | | | |
| arithmetic mean | 30.5 | | 30.5 |
| standard deviation | ± 2.3 | ± | ± 2.3 |
| Waist circumference | | | |
| Waist circumference was measured at the midpoint between the lateral iliac crest and lowest rib, during expiration. The measuring tape was to be snug but not compressing the skin and held parallel to the floor. The measurement was to be made during normal respiration. | | | |

| | | | |
|---|--------|---|--------|
| Units: cm | | | |
| arithmetic mean | 110.2 | | 110.2 |
| standard deviation | ± 7.3 | ± | ± 7.3 |
| Fat mass (absolute) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 35.51 | | 35.51 |
| standard deviation | ± 8.58 | ± | ± 8.58 |
| Fat mass (relative) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: percentage | | | |
| arithmetic mean | 38.35 | | 38.35 |
| standard deviation | ± 7.57 | ± | ± 7.57 |
| Fat free mass (absolute) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 56.70 | | 56.70 |
| standard deviation | ± 7.79 | ± | ± 7.79 |
| Fat free mass (relative) | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: percentage | | | |
| arithmetic mean | 61.65 | | 61.65 |
| standard deviation | ± 7.57 | ± | ± 7.57 |
| Body mass | | | |
| The Bod Pod® (Cosmed) was used to determine body composition and measure fat mass, fat-free mass, and total body mass via whole body densitometry. Measurements were made with the subject sitting inside a comfortable chamber, for two 50-second measurements; the total duration of the procedure was approximately 5 minutes. | | | |
| Units: kg | | | |
| arithmetic mean | 92.20 | | 92.20 |
| standard deviation | ± 9.30 | ± | ± 9.30 |

End points

End points reporting groups

| | |
|--|--------------------|
| Reporting group title | Elafibranor 120 mg |
| Reporting group description: Elafibranor 120 mg tablet qd | |
| Reporting group title | Placebo |
| Reporting group description: Matched placebo tablet qd | |
| Subject analysis set title | ITT set |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: All the subjects that were randomized. | |
| Subject analysis set title | PP set |
| Subject analysis set type | Per protocol |
| Subject analysis set description: All randomized subjects who completed the study without any major protocol deviation affecting the primary efficacy endpoint. | |
| Subject analysis set title | Safety set |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: All subjects who received at least one dose of study treatment. | |

Primary: relative amount of saturated fatty acid in the liver (%SFA) at the end of each 6-week treatment period

| | |
|--|---|
| End point title | relative amount of saturated fatty acid in the liver (%SFA) at the end of each 6-week treatment period ^[1] |
| End point description: The primary endpoint was the relative amount of SFA in the liver (%SFA) measured by 1H-MRS at the end of each 6-week treatment period. | |
| End point type | Primary |
| End point timeframe: Visit 3 and Visit 6 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No efficacy analyses produced as the number of subjects who completed the study was insufficient.

| End point values | Elafibranor 120 mg | Placebo | | |
|--------------------------------------|--------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[2] | 0 ^[3] | | |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | | |

Notes:

[2] - analysis not performed due to lack of data

[3] - analysis not performed due to lack of data

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline achieved after 6 weeks of treatment in Polyunsaturated Fatty Acids (PUFA)

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in Polyunsaturated Fatty Acids (PUFA) ^[4] |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Visit 3 and Visit 6

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No efficacy analyses produced as the number of subjects who completed the study was insufficient.

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[5] | 0 ^[6] | 0 ^[7] | 0 ^[8] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[5] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[6] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[7] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[8] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline achieved after 6 weeks of treatment in Monounsaturated Fatty Acids (MUFA)

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in Monounsaturated Fatty Acids (MUFA) ^[9] |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Visit 3 and Visit 6

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No efficacy analyses produced as the number of subjects who completed the study was insufficient.

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[10] | 0 ^[11] | 0 ^[12] | 0 ^[13] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[10] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[11] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[12] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[13] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline achieved after 6 weeks of treatment in Saturated Fatty Acids (SFA)

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in Saturated Fatty Acids (SFA) ^[14] |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Visit 3 and Visit 6

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No efficacy analyses produced as the number of subjects who completed the study was insufficient.

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[15] | 0 ^[16] | 0 ^[17] | 0 ^[18] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[15] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[16] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[17] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[18] - No efficacy analyses produced as the number of subjects who completed the study was

insufficient.

Statistical analyses

No statistical analyses for this end point

Primary: Change from baseline achieved after 6 weeks of treatment in MRS liver fat fraction (%Fat w/w)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in MRS liver fat fraction (%Fat w/w) ^[19] |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Visit 3 and Visit 6

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No efficacy analyses produced as the number of subjects who completed the study was insufficient.

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[20] | 0 ^[21] | 0 ^[22] | 0 ^[23] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[20] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[21] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[22] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[23] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Hepatic Glucose Production (HGP) at the end of each 6-week treatment period

| | |
|-----------------|---|
| End point title | Hepatic Glucose Production (HGP) at the end of each 6-week treatment period |
|-----------------|---|

End point description:

Hepatic glucose production at the end of each 6-week treatment period was used as a measure of hepatic insulin sensitivity.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[24] | 0 ^[25] | 0 ^[26] | 0 ^[27] |
| Units: µmol/kg/min | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[24] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[25] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[26] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[27] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in HbA1c

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in HbA1c |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[28] | 0 ^[29] | 0 ^[30] | 0 ^[31] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[28] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[29] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[30] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[31] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in fasting plasma glucose (FPG)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in fasting plasma glucose (FPG) |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[32] | 0 ^[33] | 0 ^[34] | 0 ^[35] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[32] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[33] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[34] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[35] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in fasting insulin

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[36] | 0 ^[37] | 0 ^[38] | 0 ^[39] |
| Units: pmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[36] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[37] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[38] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[39] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in HOMA-IR

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in HOMA-IR |
|-----------------|---|

End point description:

HOMA-IR: homeostasis model assessment of insulin resistance

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[40] | 0 ^[41] | 0 ^[42] | 0 ^[43] |
| Units: index | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[40] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[41] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[42] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[43] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in fructosamine

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in fructosamine |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[44] | 0 ^[45] | 0 ^[46] | 0 ^[47] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[44] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[45] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[46] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[47] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in C-peptide

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in C-peptide |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[48] | 0 ^[49] | 0 ^[50] | 0 ^[51] |
| Units: nmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[48] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[49] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[50] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[51] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in total cholesterol

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in total cholesterol |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[52] | 0 ^[53] | 0 ^[54] | 0 ^[55] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[52] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[53] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[54] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[55] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in HDL cholesterol (HDL-C)

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in HDL cholesterol (HDL-C) |
|-----------------|---|

End point description:

HDL: high density lipoprotein

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[56] | 0 ^[57] | 0 ^[58] | 0 ^[59] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[56] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[57] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[58] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[59] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in non-HDL cholesterol

| | |
|--|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in non-HDL cholesterol |
| End point description: Secondary endpoints were measured at the end of each of the 6-week treatment periods | |
| End point type | Secondary |
| End point timeframe: Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[60] | 0 ^[61] | 0 ^[62] | 0 ^[63] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[60] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[61] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[62] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[63] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in LDL cholesterol (calculated)

| | |
|--|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in LDL cholesterol (calculated) |
| End point description: LDL: low density lipoprotein Secondary endpoints were measured at the end of each of the 6-week treatment periods | |
| End point type | Secondary |
| End point timeframe: Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[64] | 0 ^[65] | 0 ^[66] | 0 ^[67] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[64] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[65] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[66] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[67] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in fasting triglycerides

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in fasting triglycerides |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[68] | 0 ^[69] | 0 ^[70] | 0 ^[71] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[68] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[69] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[70] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[71] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in free fatty acid

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in free fatty acid |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[72] | 0 ^[73] | 0 ^[74] | 0 ^[75] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[72] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[73] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[74] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[75] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in high-sensitivity C-reactive protein hsCRP

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in high-sensitivity C-reactive protein hsCRP |
|-----------------|---|

End point description:

hs-CRP: high sensitivity C-reactive protein

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[76] | 0 ^[77] | 0 ^[78] | 0 ^[79] |
| Units: mg/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[76] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[77] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[78] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[79] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in fibrinogen

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in fibrinogen |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[80] | 0 ^[81] | 0 ^[82] | 0 ^[83] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[80] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[81] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[82] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[83] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in haptoglobin

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in haptoglobin |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[84] | 0 ^[85] | 0 ^[86] | 0 ^[87] |
| Units: g/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[84] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[85] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[86] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[87] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in gamma-glutamyl transferase (GGT)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in gamma-glutamyl transferase (GGT) |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[88] | 0 ^[89] | 0 ^[90] | 0 ^[91] |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[88] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[89] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[90] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[91] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in aspartate aminotransferase (AST)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in aspartate aminotransferase (AST) |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[92] | 0 ^[93] | 0 ^[94] | 0 ^[95] |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[92] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[93] - No efficacy analyses produced as the number of subjects who completed the study was

insufficient.

[94] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[95] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in alanine aminotransferase (ALT)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in alanine aminotransferase (ALT) |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|-------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[96] | 0 ^[97] | 0 ^[98] | 0 ^[99] |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[96] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[97] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[98] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[99] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in alkaline phosphatase

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in alkaline phosphatase |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[100] | 0 ^[101] | 0 ^[102] | 0 ^[103] |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[100] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[101] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[102] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[103] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in total bilirubin

| | |
|--|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in total bilirubin |
| End point description: | |
| Secondary endpoints were measured at the end of each of the 6-week treatment periods | |
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[104] | 0 ^[105] | 0 ^[106] | 0 ^[107] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[104] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[105] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[106] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[107] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in conjugated bilirubin

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in conjugated bilirubin |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[108] | 0 ^[109] | 0 ^[110] | 0 ^[111] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[108] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[109] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[110] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[111] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in serum creatinine

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in serum creatinine |
|-----------------|--|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[112] | 0 ^[113] | 0 ^[114] | 0 ^[115] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[112] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[113] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[114] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[115] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in eGFR

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in eGFR |
|-----------------|--|

End point description:

eGFR, i.e. estimated glomerular filtration rate, was calculated according to the MDRD (Modification of Diet in Renal Disease) equation.

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[116] | 0 ^[117] | 0 ^[118] | 0 ^[119] |
| Units: mL/min/1.73m ² | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[116] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[117] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[118] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[119] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in albumin

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in albumin |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[120] | 0 ^[121] | 0 ^[122] | 0 ^[123] |
| Units: g/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[120] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[121] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[122] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[123] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in total protein

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in total protein |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[124] | 0 ^[125] | 0 ^[126] | 0 ^[127] |
| Units: g/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[124] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[125] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[126] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[127] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in urea (BUN)

| | |
|-----------------|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in urea (BUN) |
|-----------------|--|

End point description:

Urea: blood urea nitrogen

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[128] | 0 ^[129] | 0 ^[130] | 0 ^[131] |
| Units: mmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[128] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[129] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[130] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[131] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in uric acid

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in uric acid |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[132] | 0 ^[133] | 0 ^[134] | 0 ^[135] |
| Units: µmol/L | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[132] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[133] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[134] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[135] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in body weight

| | |
|-----------------|---|
| End point title | Change from baseline achieved after 6 weeks of treatment in body weight |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 and Visit 6 | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[136] | 0 ^[137] | 0 ^[138] | 0 ^[139] |
| Units: kg | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[136] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[137] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[138] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[139] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline achieved after 6 weeks of treatment in Body Mass Index (BMI)

| | | |
|--|---|--|
| End point title | Change from baseline achieved after 6 weeks of treatment in Body Mass Index (BMI) | |
| End point description: | | |
| Secondary endpoints were measured at the end of each of the 6-week treatment periods | | |
| End point type | Secondary | |
| End point timeframe: | | |
| Visit 3 and Visit 6 | | |

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[140] | 0 ^[141] | 0 ^[142] | 0 ^[143] |
| Units: kg/m2 | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[140] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[141] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[142] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[143] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: Waist circumference Change from baseline at the end of each 6-week treatment period

| | |
|-----------------|---|
| End point title | Waist circumference Change from baseline at the end of each 6-week treatment period |
|-----------------|---|

End point description:

Secondary endpoints were measured at the end of each of the 6-week treatment periods

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 3 and Visit 6

| End point values | Elafibranor 120 mg | Placebo | ITT set | PP set |
|--------------------------------------|--------------------|--------------------|----------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 0 ^[144] | 0 ^[145] | 0 ^[146] | 0 ^[147] |
| Units: cm | | | | |
| arithmetic mean (standard deviation) | () | () | () | () |

Notes:

[144] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[145] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[146] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

[147] - No efficacy analyses produced as the number of subjects who completed the study was insufficient.

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant hematology parameter abnormality

| | |
|-----------------|--|
| End point title | incidence of clinically significant hematology parameter abnormality |
|-----------------|--|

End point description:

abnormalities considered clinically significant by the PI.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: from the first screening visit until Visit 6 of the second treatment period | |

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with abnormalities | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant chemistry, liver function and renal function parameter abnormality

| | |
|---|--|
| End point title | incidence of clinically significant chemistry, liver function and renal function parameter abnormality |
| End point description: abnormalities considered clinically significant by the PI | |
| End point type | Secondary |
| End point timeframe: from the first screening visit until Visit 6 of the second treatment period | |

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with abnormalities | 2 | 2 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant vital signs abnormality

| | |
|---|---|
| End point title | incidence of clinically significant vital signs abnormality |
| End point description: abnormalities considered clinically significant by the PI | |

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: from the first screening visit until Visit 6 of the second treatment period | |

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with abnormalities | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant change in diet

| | |
|---|--|
| End point title | incidence of clinically significant change in diet |
| End point description: changes considered clinically significant by the PI | |
| End point type | Secondary |
| End point timeframe: from the first screening visit until Visit 6 of the second treatment period | |

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with CS change | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant change in alcohol consumption

| | |
|---|---|
| End point title | incidence of clinically significant change in alcohol consumption |
| End point description: changes considered clinically significant by the PI | |
| End point type | Secondary |

End point timeframe:
from the first screening visit until Visit 6 of the second treatment period

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with CS change | 1 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of clinically significant change in physical activity

End point title incidence of clinically significant change in physical activity

End point description:
changes considered clinically significant by the PI

End point type Secondary

End point timeframe:
from the first screening visit until Visit 6 of the second treatment period

| | | | | |
|--|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with CS change | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: incidence of strenuous and unusual exercise

End point title incidence of strenuous and unusual exercise

End point description:

End point type Secondary

End point timeframe:
from the first screening visit until Visit 6 of the second treatment period

| | | | | |
|--------------------------------------|--------------------|-----------------|--|--|
| End point values | Elafibranor 120 mg | Placebo | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with event | 0 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of adverse events

| | |
|-----------------|-----------------------------|
| End point title | Incidence of adverse events |
|-----------------|-----------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|--|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: number of subjects with a least 1 event | 12 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of treatment emergent adverse event

| | |
|-----------------|---|
| End point title | Incidence of treatment emergent adverse event |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 10 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of treatment emergent adverse events related to study treatment

| | |
|-----------------|---|
| End point title | Incidence of treatment emergent adverse events related to study treatment |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of treatment emergent adverse events related to study procedures

| | |
|-----------------|--|
| End point title | Incidence of treatment emergent adverse events related to study procedures |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of serious adverse events

| | |
|-----------------|-------------------------------------|
| End point title | Incidence of serious adverse events |
|-----------------|-------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of serious treatment emergent adverse events

| | |
|-----------------|--|
| End point title | Incidence of serious treatment emergent adverse events |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of serious treatment emergent adverse events related to study treatment

| | |
|-----------------|---|
| End point title | Incidence of serious treatment emergent adverse events related to study treatment |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | | | | |
|---|----------------------|--|--|--|
| End point values | Safety set | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of serious treatment emergent adverse events related to study procedure

| | |
|-----------------|---|
| End point title | Incidence of serious treatment emergent adverse events related to study procedure |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of adverse events leading to treatment withdrawal

| | |
|-----------------|---|
| End point title | Incidence of adverse events leading to treatment withdrawal |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of treatment emergent adverse event leading to treatment withdrawal

| | |
|-----------------|---|
| End point title | Incidence of treatment emergent adverse event leading to treatment withdrawal |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of adverse events leading to study withdrawal

| | |
|-----------------|---|
| End point title | Incidence of adverse events leading to study withdrawal |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of treatment emergent adverse events leading to study withdrawal

| | |
|-----------------|--|
| End point title | Incidence of treatment emergent adverse events leading to study withdrawal |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of fatal adverse events

| | |
|-----------------|-----------------------------------|
| End point title | Incidence of fatal adverse events |
|-----------------|-----------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of fatal treatment emergent adverse event

| | |
|-----------------|---|
| End point title | Incidence of fatal treatment emergent adverse event |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of adverse events of special interest

| | |
|-----------------|---|
| End point title | Incidence of adverse events of special interest |
|-----------------|---|

End point description:

AESI are TEAEs corresponding to the conceptual definition of:
 CPK elevations of severe intensity or leading to permanent study drug discontinuation;
 Muscle injury symptoms of severe intensity corresponding to muscle pain or myalgia, Muscle spasms or tremor, muscle weakness;
 Transaminases elevations from baseline of severe intensity or leading to permanent study drug discontinuation;
 Liver injury events of severe intensity corresponding to hepatic impairment, hepatic failure;
 Gastrointestinal symptoms of severe intensity corresponding to abdominal pain, constipation, diarrhea, nausea, vomiting, acute cholecystitis, acute pancreatitis;
 Fatigue and asthenia of severe intensity;
 Serum creatinine elevations of severe intensity or leading to permanent study drug discontinuation;
 Renal injury events of moderate or severe intensity corresponding to renal failure, renal impairment, renal colic.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| End point values | Safety set | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 17 | | | |
| Units: Number of subjects with at least 1 event | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of clinically significant change in smoking habits

| | |
|-----------------|--|
| End point title | Incidence of clinically significant change in smoking habits |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

from the first screening visit until Visit 6 of the second treatment period

| End point values | Elafibranor 120 mg | Placebo | | |
|--|--------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 13 | | |
| Units: number of subjects with CS change | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

from signature of the subject ICF at the first Screening Visit until the end of study visit

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 23.0 |

Reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | Overall population |
|-----------------------|--------------------|

Reporting group description: -

| Serious adverse events | Overall population | | |
|---|--------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 17 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Overall population | | |
|---|--------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 12 / 17 (70.59%) | | |
| Investigations | | | |
| Blood glucose increased | | | |
| subjects affected / exposed | 2 / 17 (11.76%) | | |
| occurrences (all) | 2 | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 17 (5.88%) | | |
| occurrences (all) | 1 | | |
| C-reactive protein increased | | | |
| subjects affected / exposed | 1 / 17 (5.88%) | | |
| occurrences (all) | 1 | | |
| Vascular disorders | | | |

| | | | |
|--|--|--|--|
| Arterial disorder subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 | | |
| Nervous system disorders Dizziness subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 | | |
| General disorders and administration site conditions Chest discomfort subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 | | |
| Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) Toothache subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 | | |
| Reproductive system and breast disorders Scrotal inflammation subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 | | |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Laryngitis subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 | | |
| Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 | | |

| | | | |
|---|--|--|--|
| Infections and infestations Influenza subjects affected / exposed occurrences (all) Nasopharyngitis subjects affected / exposed occurrences (all) Tooth infection subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all) | 3 / 17 (17.65%) 3 2 / 17 (11.76%) 2 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1 | | |
| Metabolism and nutrition disorders Gout subjects affected / exposed occurrences (all) | 1 / 17 (5.88%) 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 16 December 2019 | The protocol was amended in order to add an analysis set and update a series of endpoints. The changes mainly concerned: Specification of a PP set to be included for analysis purposes; inclusion of renal function and anthropometry as objectives, in line with existing endpoints; medical history was removed as a safety objective and safety endpoints were presented in more detail; specification that whole body insulin sensitivity rather than glucose infusion rate at the end of 6 weeks of treatment would be assessed as an exploratory objective and endpoint, with details of assessment parameters included; specification that waist circumference was to be assessed at the end of each 6-week treatment period, rather than as change from baseline; clarification of various other endpoints. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|--------------|--|--------------|
| 14 July 2020 | Due to the COVID-19 pandemic, subjects had difficulty visiting the study site due to lockdown rules and travel restrictions, so the study was put on hold on 15 March 2019. The sponsor then decided to prematurely terminate this study on 14 July 2020 (IEC and Regulatory Authority notified on 14 August 2020) due to lack of efficacy, but not due to safety concerns, seen in the interim results from the Phase 3 RESOLVE-IT study in subjects with NASH published on 11 May 2020. As a result of this premature termination the remaining 11 subjects did not complete this study. | - |

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to the premature termination of this study no efficacy analyses were conducted since too few subjects completed both study periods. As such the efficacy objectives were not met and no conclusions can be drawn from the efficacy data.

Notes: